Dr. Jaillon obtained a PhD in immunology in 2007 (University of Angers (France), French Institute of Health and Medical Research (INSERM, Angers (France)). In 2016, he became Assistant Professor at Humanitas University (Pieve Emanuele, Milan, Italy) and leads his own research group. In 2021 he was appointed as Associate Professor at Humanitas University. He is co-author in 40 PubMed-registered manuscripts including publications in prime journals (e.g Cell, Nature, Immunity, J Exp Med, Blood, Nat Rev Cancer, Nat Rev Immunol), underlining his leadership and outstanding contribution in the fields of innate immunity, inflammation and cancer. The research activity of Dr. Jaillon focused on cellular and molecular mechanisms involved in innate immunity and inflammation and their role in health and diseases, including cancer and infectious diseases. In particular, Dr. Jaillon redefined the role played by neutrophils in innate immunity and cancer. For instance, his first publication in 2007 demonstrated that a component of the humoral innate immunity was stored in neutrophil granules and neutrophil extracellular traps and was fundamental for neutrophil-mediated resistance against a fungal infection (Jaillon S., et al. J Exp Med, 2007). Neutrophils are “unsung heroes” in immunology and have long been viewed as short-lived effector cells with activities restricted to the acute inflammatory response and to the elimination of extracellular pathogens. Dr. Jaillon revised this dogma placing the neutrophils as an important player in the activation and regulation of both innate and adaptive immune responses, underlining the importance to study and dissect accurately the role played by neutrophils in health and diseases, including cancer (Beauvillain C., et al. Blood, 2011; Mantovani A., et al. Nat Rev Immunol, 2011; Ponzetta A., et al. Cell, 2019; Jaillon S., et al. Nat Rev Cancer, 2020). His group unveiled that the assessment of tumor-associated neutrophils may help identifying colorectal cancer patients likely to benefit from chemotherapy (Galdiero M.R. et al., Int J Cancer, 2016). Most recently, his work has highlighted a novel axis in antitumor immunity, in which neutrophils modulate the polarisation of a previously unknown subset of unconventional T cells (Ponzetta A. et al, Cell, 2019). This result represents an important breakthrough in cancer research, unmasking new potential therapeutic and prognostic approaches. It should be also underlined that Dr. Jaillon obtained highly competitive grants from the Italian Association for Cancer Research (AIRC) in 2017 and 2020, from the Italian Ministry of Health in 2018 and from the Italian Ministry of Education, Universities and Research in 2019. He also received in 2012 a Post-doctoral Investigator Award from the International Cytokine Society (ICS) and has been awarded by fellowships from French public and private associations and from the Italian Society of Immunology Clinical Immunology and Allergology (SIICA).